BioSpecifics Technologies Corp (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a collagenase-based product marketed as XIAFLEX in the US and Xiapex in Europe, announced on Friday its financial results for the third quarter ended 30 September 2018.
The company reported net income of USD5m, or USD0.69 per basic share and USD0.69 per share on a fully diluted basis, for the third quarter ended 30 September 2018, compared to net income of USD2.7m or USD0.38 per basic share and USD0.37 per share on a fully diluted basis, in the same period in 2017.
The firm posted total revenue for the third quarter ended 30 September 2018 at USD8.2m compared to USD6.5m in the year-ago period.
As of 30 September 2018, BioSpecifics had cash and cash equivalents and investments of USD77.0m, compared to USD65.1m as of 31 December 2017.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development